This site is intended for Healthcare Professionals only.

Novo Nordisk warns of supply constraints on its best-selling diabetes drug

Date:

Share post:

Danish drug developer Novo Nordisk on Wednesday (February 1) warned of supply constraints on its best-selling drug.

The company, which develops diabetes and obesity drugs, said it expected “periodic supply constraints” this year, partly driven by higher than expected demand for its blockbuster diabetes drug, Ozempic, and manufacturing constraints.

“Supply of Ozempic cannot keep up with demand in some markets,” Novo’s Chief Financial Officer Karsten Munk Knudsen told journalists on Wednesday, but said Ozempic was available in the United States, the firm’s biggest single market.

Shortages of human growth hormone would also cause sales in its rare disease franchise to drop by a “mid-single digit” percentage in 2023, as its Norditropin drug would be out of stock in certain markets, Knudsen said.

Sales of Novo Nordisk‘s new obesity drug, Wegovy, grew nearly 300 per cent in local currencies last year, despite having faced serious supply issues throughout the year.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Superdrug to open 25 new high street stores this year

The opening of new Superdrug stores is anticipated to generate over 500 jobs nationwide Superdrug is bolstering its physical...

New Hospital Scheme delays drain millions monthly from ‘scarce’ NHS funds, trust leaders warn

Trust leaders are calling on the next government to commit to constructing 40 new hospitals in England by...

NHS virtual wards set to slash waiting times, prevent 178k admissions in next 2 years

Under the new NHS virtual wards scheme, hospitals to be incentivised for prompt care, with 12-hour A&E target In...

Pharmacist Support: Trainee pharmacists get set to ACTNow for mental health awareness ahead of GPhC assessment

Pharmacist Support's annual mental health awareness campaign offers vital support ahead of GPhC assessment and registration transition Trainee pharmacists...